Clicky

EyePoint Pharmaceuticals, Inc.(EYPT)

Description: EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials. It also offers Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. In addition, the company has developed DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. Further, it develops YUTIQ shorter-actinguveitis for the treatment of posterior segment uveitis; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Additionally, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It sells its products primarily in the United States and Europe. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, and Enigma Therapeutics Limited. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.


Keywords: Medicine Biopharmaceutical Organic Compounds Inflammation Eye Macular Degeneration Chronic Disease Ophthalmic Suspension Eye Diseases Tyrosine Kinase Wet Age Related Macular Degeneration Diabetic Macular Edema Macular Edema Ophthalmic Products Uveitis Retinitis Glucocorticoids Pregnanes Ophthalmic Product Dexamethasone Treatment Of Eye Diseases Diketones Cytomegalovirus Retinitis Fluocinolone

Home Page: eyepointpharma.com

EYPT Technical Analysis

480 Pleasant Street
Watertown, MA 02472
United States
Phone: 617 926 5000


Officers

Name Title
Ms. Nancy S. Lurker Pres, CEO & Director
Mr. George O. Elston Chief Financial Officer
Dr. Jay S. Duker M.D. Chief Operating Officer
Mr. David Scott Jones Sr. VP & Chief Commercial Officer
Mr. Said Saim Chief Technology Officer
Mr. Ron I. Honig Esq. Chief Legal Officer & Company Sec.
Mr. Michael Pine Chief Corp. Devel. & Strategy Officer
Ms. Jennifer Leonard Chief People Officer & Sr. VP of IT
Dr. Dario A. Paggiarino Sr. VP & Chief Medical Officer
Ms. Isabelle Lefebvre Chief Regulatory Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.7274
Price-to-Sales TTM: 2.1535
IPO Date: 2005-01-27
Fiscal Year End: December
Full Time Employees: 122
Back to stocks